IP Library › Granted Patent US 10,150,805
Granted Patent B2
US 10,150,805 · App. 15/083,998 · Granted Dec 11, 2018

Multimeric IL-15 soluble fusion molecules and methods of making and using same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,150,805
App. No.
15/083,998
Granted
Dec 11, 2018
Kind
B2
Abstract

The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor α/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).

Claims (20)

1. An IL-15 receptor fusion polypeptide comprising an IL-15 receptor alpha sushi-binding domain fused to an Fc domain (IL-15RaSu/Fc) and a variant interleukin-15 polypeptide comprising an N72D mutation (IL-15N72D) complex (IL-15N72D:IL-15RaSu/Fc; Alt-803) comprising a dimeric IL-15RaSu/Fc and two IL-15N72D molecules.

2. The polypeptide of claim 1 , wherein the IL-15RaSu/Fc comprises SEQ ID NO: 1.

3. The polypeptide of claim 2 , wherein amino acids 1-65 of SEQ ID NO: 1 comprise IL-15RaSu.

4. The polypeptide of claim 3 , wherein amino acids 66-297 of SEQ ID NO: 1 comprise IgG1 CH2-CH3 (Fc domain).

5. The polypeptide of claim 2 , wherein amino acids 20-84 of SEQ ID NO: 4 comprise IL-15RaSu.

6. The polypeptide of claim 5 , wherein amino acids 85-316 comprise IgG1 CH2-CH3 (Fc domain).

7. The polypeptide of claim 1 , wherein the IL-15N72D comprises SEQ ID NO: 2.

8. A nucleic acid sequence encoding the polypeptide of claim 1 .

9. A nucleic acid sequence encoding an IL-15 receptor fusion polypeptide comprising an IL-15RaSu/Fc and an IL-15N72D complex (IL-15N72D:IL-15RaSu/Fc; Alt-803), wherein the nucleic acid sequence encoding IL-15RaSu/Fc comprises SEQ ID NO: 57, and wherein the nucleic acid sequence encoding IL-15N72D comprises SEQ ID NO: 56.

10. The polypeptide of claim 1 , wherein the IL-15RaSu/Fc comprises SEQ ID NO: 4.

11. The polypeptide of claim 1 , wherein the IL-15N72D comprises SEQ ID NO: 3.

12. A nucleic acid sequence encoding the polypeptide of claim 2 .

13. A nucleic acid sequence encoding the polypeptide of claim 3 .

14. A nucleic acid sequence encoding the polypeptide of claim 4 .

15. A nucleic acid sequence encoding the polypeptide of claim 5 .

16. A nucleic acid sequence encoding the polypeptide of claim 10 .

17. A nucleic acid sequence encoding the polypeptide of claim 11 .

18. The nucleic acid sequence of claim 9 , wherein the nucleic acid sequence encoding IL-15N72D comprises nucleic acids 61 to 402 of SEQ ID NO: 56.

19. The nucleic acid sequence of claim 9 , wherein the nucleic acid sequence encoding the IL-15RaSu/Fc comprises nucleic acids 58 to 948 SEQ ID NO: 57.

20. The polypeptide of claim 11 , wherein the IL-15N72D comprises amino acids 21 to 134 of SEQ ID NO: 3.

Assignments (3)
SECURITY INTEREST Recorded Jan 2, 2024
From: IMMUNITYBIO, INC.; NANTCELL, INC.; RECEPTOME, INC.; VBC HOLDINGS LLC; ALTOR BIOSCIENCE, LLC; ETUBICS CORPORATION; IGDRASOL, INC.
To: INFINITY SA LLC, AS PURCHASER AGENT
Reel/Frame 066179/0074 →
MERGER Recorded Nov 5, 2018
From: ALTOR BIOSCIENCE CORPORATION
To: ALTOR BIOSCIENCE, LLC
Reel/Frame 049949/0802 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 23, 2018
From: WONG, HING C.; RHODE, PETER, DR.; LIU, BAI; ZHU, XIAOYUN, MR.; HAN, KAI-PING, MR.
To: ALTOR BIOSCIENCE CORPORATION
Reel/Frame 045021/0809 →
Cited By (11)
US 12,186,372 US 12,233,116 US 12,241,087 US 12,268,731 US 12,268,732 US 12,280,120 US 12,318,432 US 12,344,655 US 12,371,472 US 12,410,224 US 12,662,520